# Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours

> **NCT01795768** · PHASE2 · UNKNOWN · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 48 (estimated)

## Conditions studied

- Gastric Cancer
- Oesophageal Cancer
- Breast Cancer
- Squamous Cell Carcinoma of the Lung

## Interventions

- **DRUG:** AZD 4547

## Key facts

- **NCT ID:** NCT01795768
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2014-09
- **Final completion:** 2015-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2013-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01795768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01795768, "Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01795768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*